The short answer
CBD may add to cyclobenzaprine-related drowsiness or impairment. Cannabis products containing THC can also impair alertness, but CBD and whole-cannabis preparations are not interchangeable and the exact combined risk is unmeasured.
What this answer covers
Cannabidiol is the exact pair node; the current claim also mentions Cannabis sativa. Purified CBD, THC-containing products, hemp foods and topical products require separate interpretation.
- Supplement or preparation
- Cannabidiol
- Medication ingredient
- cyclobenzaprine
CBD has preparation-specific sedation evidence
Prescription oral cannabidiol can cause somnolence and its label warns about other CNS depressants. Those epilepsy-treatment doses and co-medications do not establish the added risk from a retail CBD product with cyclobenzaprine.
Whole cannabis adds different variables
An oral study found greater impairment with THC plus high-dose CBD than with THC alone. It had no CBD-only arm and included a probe-drug cocktail. It cannot be used to say that every cannabis or hemp preparation has the same effect.
The cyclobenzaprine formulation matters
Immediate-release tablets, extended-release capsules and Tonmya sublingual tablets have different instructions and indications. All carry CNS-effect precautions; none supplies a safe cannabinoid dose or protective interval for this pair.
Review co-use and avoid impaired driving
Show the prescriber the product’s CBD/THC content and route. Avoid driving while drowsy or impaired, and seek urgent help for severe confusion, breathing difficulty or inability to wake. Do not change cyclobenzaprine dosing yourself.
Evidence and practical considerations
Side effects & toxicity
Conditional additive-impairment concern for CBD and separately THC-containing preparations. Bundled CBD/Cannabis wording narrowed by exact ingredient, route and dose; no universal hemp effect or pair incidence.
- Exact scope
- Cannabidiol is the exact pair node; the current claim also mentions Cannabis sativa. Purified CBD, THC-containing products, hemp foods and topical products require separate interpretation. with Cyclobenzaprine21949 IN; hydrochloride swallowed IR/ER and sublingual products with formulation-specific indications.
- Medication form and route
- oral medication; sublingual medication; oral supplement
What remains uncertain
- No unmeasured pair incidence, blanket class transfer or arbitrary spacing interval.
Factors that may matter: Preparation; Dose; Other medicines; Organ function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS-depressant and serotonin-syndrome warnings; concomitant MAOIs and14days after stopping contraindicated.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Not extended-release or sublingual dosing; supplement-specific risk unmeasured.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS-depressant and serotonergic precautions; MAOI contraindication.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Different release/directions from immediate-release and sublingual products.
Source 3: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cyclobenzaprine
CNS depression and serotonergic precautions; MAOI contraindication retained.
How this applies: Exact cyclobenzaprine RxCUI 21949 IN, with stated salt/formulation/route bridge.
Not swallowed-tablet dosing; sublingual product administration instructions are not a universal supplement-separation rule.
Source 4: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed cannabidiol
Dose-related somnolence/sedation, influenced by co-medication; other CNS depressants may increase it.
How this applies: CBD-specific sedation evidence with preparation/dose limits.
Prescription purified oral CBD epilepsy doses, not retail CBD or exact cyclobenzaprine co-use. No combination incidence.
Source 5: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 18 healthy adults.
CBD-containing cannabis condition produced more sedation and impairment than THC alone; placebo-cocktail condition had no measured PD effects.
How this applies: Composition-dependent cannabinoid impairment, not exact cyclobenzaprine interaction.
THC 20 mg plus CBD 640 mg oral condition with five-drug probe cocktail; no CBD-only arm and no cyclobenzaprine. Not all cannabis routes.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact cyclobenzaprine article with formulation-specific evidence and uncertainty. | |
| Research summary published |
Article revision: 8dfee4b7cd97fc4a
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.